33172, Officer: Francisco Celedon, President (Qualifying Individual) Total Freight Service Inc., 10640 Daines Drive, Temple City, CA 91780, Officer: Xiao Ming Yao, Account Manager (Qualifying Individual)

Freightsmart.com, Inc. d/b/a Saskia Container Lines, 4615 Post Oak Place, Suite 145, Houston, TX 77027, Officers: William M. Staib, President (Qualifying Individual), Ofer Levy, Vice President

Miami Shipping Services Inc., 6225 S.W. 87th Avenue, Miami, FL 33173, Officer: Ricardo Arango, President (Qualifying Individual)

Mar-Line Co., 3400 Mesa Drive, Houston, TX 77013–3820, Officers: Hector Garza, President (Qualifying Individual), Gloria Razo, Vice President

Trans State Logistics, Inc., 3734 W. Century Blvd., Unit #7, Inglewood, CA 90303, Officers: Samantha Nguyen, Secretary (Qualifying Individual), Kan Shing Cheng, CEO

Simpson's Shipping Enterprise, 166 West First Street, Mount Vernon, NY 10550, Officers: George Simpson, Active Management Partner (Qualifying Individual), Linda Morris Simpson, Partner

Non-Vessel Operating Common Carrier and Ocean Freight Forwarder Transportation Intermediary Applicants

Trans-Am Container Line, Inc., 116 W. Hazel Street, Inglewood, CA 90302, Officers: Chan, Cheuk See, Vice President (Qualifying Individual), Lam, Yuen Sum, President

Sofilink Logistics Incorporated, 6810 N.W. 82nd Avenue, Miami, FL 33166, Officer: Nelson A. Guillen, President (Qualifying Individual)

Distribution Support Systems, Inc., 6454 East Taft Road, East Syracuse, NY 13057, Officer: James J. Duffy, President (Qualifying Individual)

Vipex Consolidators, Inc., 8478 N.W. 72nd Street, Miami, FL 33166, Officer: Maria del Carmen Rodriguez, President (Qualifying Individual)

New World Logistics, Inc., 1304 Municipal Drive, Roanoke, VA 24012, Officer: Rickey Gene Roberts, President (Qualifying Individual)

Ocean Freight Forwarder—Ocean Transportation Intermediary Applicants

Manila Forwarders, LLC, 3916 Eagle Rock Blvd., Los Angeles, CA 90065, Officers: Manuel Paez, President (Qualifying Individual), George de Guzman, Director

South Florida Auto Terminal d/b/a Autoterminal.com, 4401 McIntosh Drive, Ft. Lauderdale, FL 33316, Officers: Mercedes Leone, Secretary (Qualifying Individual)

Dockside Management, Inc., 8405 N.W. 53rd Street, Suite A–104 Miami, FL 33166, Officer: Clara M. Faya, Vice President (Qualifying Individual)

Allegheny Brokers Company, Inc., 5389 C.V. Jackson Road, Suite #1 New River Valley Airport, Dublin, VA 24084, Officers: Mathews C. Herring, Vice President (Qualifying Individual), James Loux, President

Mares Shreve & Associates Inc., 1035 Andover Park West, Suite 110, Tukwila, WA 98188, Officers: Janice L. Williams, President (Qualifying Individual), Daniel A. Sanchez, Vice President

March 30, 2001.

Bryant L. VanBrakle,

Secretary.

[FR Doc. 01–8289 Filed 4–3–01; 8:45 am] **BILLING CODE 6730–01–P**

FEDERAL RESERVE SYSTEM

Sunshine Act Meeting

AGENCY HOLDING THE MEETING: Board of Governors of the Federal Reserve System.

TIME AND DATE: 11:00 a.m., Monday, April 9, 2001.

PLACE: Marriner S. Eccles Federal Reserve Board Building, 20th and C Streets, NW., Washington, DC 20551.

STATUS: Closed.

MATTERS TO BE CONSIDERED:

- 1. Personnel actions (appointments, promotions, assignments, reassignments, and salary actions) involving individual Federal Reserve System employees.
- 2. Any items carried forward from a previously announced meeting.

CONTACT PERSON FOR MORE INFORMATION: Lynn S. Fox, Assistant to the Board; 202–452–3204.

SUPPLEMENTARY INFORMATION: You may call 202–452–3206 beginning at approximately 5 p.m. two business days before the meeting for a recorded announcement of bank and bank holding company applications scheduled for the meeting; or you may contact the Board's Web site at http://www.federalreserve.gov for an electronic announcement that not only lists applications, but also indicates procedural and other information about the meeting.

Dated: March 30, 2001.

Robert deV. Frierson,

Associate Secretary of the Board. [FR Doc. 01–8388 Filed 4–2–01; 10:30 am] BILLING CODE 6210–01–P

FEDERAL RETIREMENT THRIFT INVESTMENT BOARD

Sunshine Act Meeting

TIME AND DATE: 10 a.m. (EDT); April 9, 2001.

PLACE: 4th Floor, Conference Room 4506, 1250 H Street, NW., Washington, DC.

STATUS: Open.

MATTERS TO BE CONSIDERED:

- 1. Approval of the minutes of the March 12, 2001, Board member meeting.
- 2. Thrift Savings Plan activity report by the Executive Director.
- 3. Review of Arthur Andersen annual financial audit.

CONTACT PERSON FOR MORE INFORMATION:

Thomas J. Trabucco, Director, Office of External Affairs, (202) 942–1640.

Dated: April 2, 2001.

Elizabeth S. Woodruff.

Secretary to the Board, Federal Retirement Thrift Investment Board.

[FR Doc. 01–8430 Filed 4–2–01; 2:50 pm]

FEDERAL TRADE COMMISSION

Granting of Request for Early Termination of the Waiting Period Under the Premerger Notification Rules

Section 7A of the Clayton Act, 15 U.S.C. 18a, as added by Title II of the Hart-Scott-Rodino Antitrust Improvements Act of 1976, requires persons contemplating certain mergers or acquisitions to give the Federal Trade Commission and the Assistant Attorney General advance notice and to wait designated periods before consummation of such plans. Section 7A(b)(2) of the Act permits the agencies, in individual cases, to terminate this waiting period prior to its expiration and requires that notice of this action be published in the **Federal Register**.

The following transactions were granted early termination of the waiting period provided by law and the premerger notification rules. The grants were made by the Federal Trade Commission and the Assistant Attorney General for the Antitrust Division of the Department of Justice. Neither agency intends to take any action with respect

to these proposed acquisitions during the applicable waiting period.

Trans #	Acquiring	Acquired	Entities
	Transactions Grantee	d Early Termination—03/05/2001	I
20011132	Lhoist S.A.	Baker Holding Company	Baker Holding Company.
	Transactions Grante	d Early Termination—03/06/2001	
20011513	SBC Communications Inc	SBC Communications Inc	Washington Baltimore Limited Part
20011521	Citigroup Inc	Fairchild Semiconductor Inter-	nership. Fairchild Semiconductor Internationa
20011525	Wellspring Capital Partners II, L.P	national, Inc. Gilberto Marin Quintero	Inc. Grupo P.I. Mabe S.A. de C.V., Paragon-Mabesa International, S.A. de C.V., Stronger Corporation S.A.
	Transactions Grante	d Early Termination—03/09/2001	
20011529 20011530 20011534	Ameritrade Holding Corporation ABN AMRO Holding N.V	Robert L. Earthman, Jr	TradeCast, Inc. TradeCast, Inc. QEK Global Solutions, L.P., QEK USA Management LLC. Paramount Financial Group, LLC,
20011549	Welsh, Carson, Anderson & Stowe VIII, L.P.	Triad Hospitals, Inc	Protech Development Corporation. Triad Hospitals, Inc.
20011553 20011561	KTC/AMG Holdings Corp	Kenan Transport Company	Kenan Transport Company. Data-Tech, Inc., United Provider Services, Inc.
20011564	WinsLoew Furniture, Inc	New Era of Networks, Inc	New Era of Networks, Inc. Brown Jordan International. Efficient Networks, Inc. D&B Investors, L.P. Century Aluminum Company.
		d Early Termination—03/12/2001	
20011533	President and Fellows of Harvard College.	International Paper Company	IP Pacific Timberlands, Inc.
20011546		Diashowa Paper Manufacturing, Co., Ltd.	Diashowa Paper Manufacturing, Co., Ltd.
20011570 20011581		Code, Hennessey & Simmons II, L.P Eaton Corporation	Globe Holdings, Inc. Eaton's Vehicle Switch/Electronics Division.
	Transactions Grante	d Early Termination—03/13/2001	
20011557		Hecla Mining Company Hecla Mining Company	Kentucky-Tennessee Clay Company, K-T Feldspar Corporation, South- eastern Land Resources Corp. Kentucky-Tennessee Clay Company, K-T Feldspar Corporation, South- eastern Land Resources Corp.
	Transactions Grante	d Early Termination—03/14/2001	
20011519	HCA—The Healthcare Company	HEALTHSOUTH Corporation	HEALTHSOUTH Corporation.
	Transactions Grante	d Early Termination—03/16/2001	
20011333 20011567	·	Trans World Airlines, Inc. (Debtor-in-Possession). II Fornaio (America) Corporation	Trans World Airlines, Inc. (Debtor-in- Possession), TWA Stock Holding Company. Il Fornaio (America) Corporation.
20011578 20011579 20011585	Ricardo J. Cisneros	America Online Latin America, Inc America Online Latin America, Inc Mr. John F. Croddick, Sr	America Online Latin America, Inc. America Online Latin America, Inc. Cosmetic Essence, Inc.
20011592 20011593 20011594	AT&T Corp	UnitedGlobalCom, Inc	UnitedGlobalCom, Inc. Quintus Corporation. Netfish Technologies, Inc.

Trans #	Acquiring	Acquired	Entities
20011596	Buhrmann N.V.	US Office Products Company	US Office Products—North America.

FOR FURTHER INFORMATION CONTACT:

Sandra M. Peay or Parcellena P. Fielding, Contact Representatives, Federal Trade Commission, Premerger Notification Office, Bureau of Competition, Room 303, Washington, DC 20580, (202) 326–3100.

By Direction of the Commission.

Donald S. Clark,

Secretary.

[FR Doc. 01–8301 Filed 4–3–01; 8:45 am]

FEDERAL TRADE COMMISSION

[File No. 002 3211]

Med Gen, Inc., et al.; Analysis To Aid Public Comment

AGENCY: Federal Trade Commission. **ACTION:** Proposed consent agreement.

SUMMARY: The consent agreement in this matter settles alleged violations of federal law prohibiting unfair or deceptive acts or practices or unfair methods of competition. The attached Analysis to Aid Public Comment describes both the allegations in the complaint that accompanies the consent agreement and the terms of the consent order—embodied in the consent agreement—that would settle these allegations.

DATES: Comments must be received on or before April 30, 2001.

ADDRESSES: Comments should be directed to: FTC/Office of the Secretary, Room 159, 600 Pennsylvania Ave., NW., Washington, D.C. 20580.

FOR FURTHER INFORMATION CONTACT:

Lemuel Dowdy or Walter Gross, FTC/S–4302, 600 Pennsylvania Ave., NW., Washington, D.C. 20580, (202) 326–2981 or 326–3319.

SUPPLEMENTARY INFORMATION: Pursuant to section 6(f) of the Federal Trade Commission Act, 38 Stat. 721, 15 U.S.C. 46 and Section 2.34 of the Commission's Rules of Practice (16 CFR 2.34), notice is hereby given that the above-captioned consent agreement containing a consent order to cease and desist, having been filed with and accepted by the Commission, has been placed on the public record for a period of thirty (30) days. The following Analysis to Aid Public Comment describes the terms of the consent agreement, and the allegations in the complaint. An electronic copy of the full text of the

consent agreement package can be obtained from the FTC Home Page (for March 29, 2001), on the World Wide Web, at "http://www.ftc.gov/os/2001/03/index.htm." A paper copy can be obtained for the FTC Public Reference Room, Room H–130, 600 Pennsylvania Avenue, NW., Washington, D.C. 20580, either in person or by calling (202) 326–3627.

Public comment is invited. Comments should be directed to: FTC/Office of the Secretary, Room 159, 600 Pennsylvania Ave., NW., Washington, D.C. 20580. Two paper copies of each comment should be filed, and should be accompanied, if possible, by a 3½ inch diskette containing an electronic copy of the comment. Such comments or views will be considered by the Commission and will be available for inspection and copying at its principal office in accordance with section 4.9(b)(6)(ii) of the Commission's Rules of Practice (16 CFR 4.9(b)(6)(ii)).

Analysis of Proposed Consent Order To Aid Public Comment

The Federal Trade Commission has accepted an agreement, subject to final approval, to a proposed consent order from Med Gen, Inc. and its president, Paul Kravitz ("proposed respondents"). Proposed respondents market "Snorenz," a dietary supplement consisting of oils and vitamins that is sprayed on the back of the throat of persons who snore.

The proposed consent order has been placed on the public record for thirty (30) days for reception of comments by interested persons. Comments received during this period will become part of the public record. After thirty (30) days, the Commission will again review the agreement and the comments received and will decide whether it should withdraw from the agreement and take other appropriate action or make final the agreement's proposed order.

The Commission's complaint charges that proposed respondents failed to have a reasonable basis for claims they made about the product's efficacy in (1) reducing or eliminating snoring or the sounds of snoring, (2) reducing or eliminating snoring or the sounds of snoring for six to eight hours, and (3) treating the symptoms of sleep apnea. The complaint also alleges that proposed respondents lacked a reasonable basis to substantiate representations that testimonials from

consumers who used Snorenz represented the typical and ordinary experience of users of the product. Proposed respondent are also charged with making false claims that clinical proof establishes the efficacy of Snorenz. Further, the complaint alleges that the proposed respondents failed to disclose adequately that the product is not intended to treat sleep apnea; that sleep apnea is a potentially lifethreatening disorder characterized by loud snoring, frequent interruptions of sleep, and daytime tiredness; and that persons experiencing those symptoms should seek medical attention. Finally, the complaint alleges that proposed respondents failed to disclose that a material connection existed between Med Gen, Inc. and a physician who appeared in the informercials to endorse Snorenz. Such claims appeared in informercials promoting Snorenz that proposed respondents produced, or caused to be produced for them,1 on Med Gen, Inc.'s website, and/or on labeling for the product.

Part I of the consent order requires that proposed respondents possess competent and reliable scientific evidence to substantiate representations that Snorenz or any other food, drug, or dietary supplement reduces or eliminates snoring or the sounds of snoring; reduces or eliminates snoring or the sounds of snoring for any specified period of time through a single application; or eliminates, reduces or mitigates the symptoms of sleep apnea. Part II of the order requires that, for any product that has not been shown to be effective in the treatment of sleep apnea, proposed respondents must affirmatively disclose, whenever they represent that a product is effective in reducing or eliminating snoring or the sounds of snoring, a warning statement about sleep apnea and the need for physician consultation. Part III of the order requires proposed respondents to substantiate any representation about the benefits, performance, efficacy, or safety of Snorenz or any other food, drug, or dietary supplement. Part IV prohibits false claims about scientific support for any product, service, or program. Part V requires that, for any consumer endorsement or testimonial proposed respondents use to promote a

¹ A separate consent settlement with a producer of several infomercials for Snorenz, Tru-Vantage International, L.L.C. (File No. 002–3210), is also being placed on the public record for comment.